# Beihai Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beihai-biotech

- Industry: Biotechnology
- Headquarters: Zhuhai, China
- Website: www.bayhibiotech.com
- Total disclosed funding: $28M
- Latest round: Series C (Dec 14, 2023)
- Investors on record: 6

## About

Established in 2013 and based in Zhuhai, China, Beihai Biotech is a biomedical company that focuses on research and development of anti-tumor drugs. The company has developed 12 authorized invention patents and more than 70 invention patent applications. Besides, it has mastered the technology to improve the solubility of poorly soluble injection drugs. Beihai Biotech won the title of Potential Enterprise in The Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area Award 2020. In June 2023, the company acquired the Drug Production License. In December 2023, Beihai Biotech closed a series C funding.

The company's main business is the development of breast cancer, non-small cell cancer, prostate cancer, anti-tumor drugs, and other anticancer drugs. Beihai Biotech owns two drug technology platforms molecular targeted delivery technology platform and PDC technology platform. Its ongoing research projects include BH009, BH002, BH006, etc.

## Funding rounds

- Series C, Dec 14, 2023 — GAINS Investment Corporation, Shenzhen Hengguan Equity Investment Fund Management
- Series B, Oct 31, 2022, $28M — Oriza Holdings, Shenzhen Guozhong Venture Capital, Zhuhai Jinhang Industrial Investment, Yikai Ventures
- Series A, Jan 6, 2022 — Shenzhen Guozhong Venture Capital, Yikai Ventures
- Angel, Jan 1, 2017 — Shenzhen Guozhong Venture Capital

## Investors

- Shenzhen Guozhong Venture Capital (https://capitalatlas.ai/funds/shenzhen-guozhong-venture-capital) — Angel, Series A, Series B
- Yikai Ventures — Series A, Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B
- Zhuhai Jinhang Industrial Investment — Series B
- GAINS Investment Corporation (https://capitalatlas.ai/funds/gains-investment-corporation) — Series C
- Shenzhen Hengguan Equity Investment Fund Management — Series C